Bruno Chapsal

Bruno Chapsal is a Principal Scientist in Medicinal Chemistry at Pfizer, where they have brought their expertise in synthetic organic chemistry to the forefront since 2022. With over six years of experience at AMRI in collaboration with Eli Lilly, Bruno has a strong background in synthesizing small drug-like molecules and catalysis. Prior to their current role, they held positions at AstraZeneca, AMRI, Purdue University, and Stony Brook University, where they contributed to various projects in medicinal chemistry and organic synthesis. Bruno holds a Ph.D. in Organic Synthesis from Stony Brook University and an M.Sc. in Chemistry and Chemical Engineering from Ecole supérieure de Chimie Physique Electronique de Lyon.